Screening for fragile X is cost effective and accurate

BMJ 1997; 315 doi: (Published 26 July 1997) Cite this as: BMJ 1997;315:205
  1. Caroline White
  1. London

    Screening for the fragile X syndrome is both accurate and cost effective and should now be considered for inclusion in a national screening programme, concludes a new report commissioned by the NHS Executive's research and development programme on health technology assessment (Journal of Medical Screening 1997;4:60-94).

    DNA testing to screen for the disorder is now technically feasible. However, although the technology has been available for some time, there has been some reluctance to …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription